P Picci

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. doi request reprint Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines
    Claudia M Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Genes Chromosomes Cancer 48:289-309. 2009
  2. pmc Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed
    Stefano Ferrari
    Anti Tumour Drugs Section Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    J Transl Med 11:268. 2013
  3. pmc An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas
    Clara Guerzoni
    PROMETEO Laboratory, Section of Biomolecular Therapies, RIT Department, Istituto Ortopedico Rizzoli, Bologna 40136, Italy
    BMC Cancer 14:137. 2014
  4. pmc Solitary fibrous tumors of the soft tissues: imaging features with histopathologic correlations
    Zafaria G Papathanassiou
    The Rizzoli Institute, via del Barbiano 1 10, 40136, Bologna, Italy
    Clin Sarcoma Res 3:1. 2013
  5. pmc Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Clin Sarcoma Res 2:4. 2012
  6. pmc Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
    Ymera Pignochino
    Division of Medical Oncology, University of Torino Medical School, A, O, Ordine Mauriziano, Institute for Cancer Research and Treatment Candiolo, and Regina Margherita Children s Hospital, Torino, Italy
    Mol Cancer 8:118. 2009
  7. pmc Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
    Melissa Paoloni
    Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 10:625. 2009
  8. pmc Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone
    Maurice Balke
    Department of Orthopaedic Surgery, University of Munster, Munster, Germany
    BMC Cancer 10:462. 2010
  9. pmc Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors
    Suvi Savola
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki, Helsinki, Finland
    BMC Cancer 9:17. 2009
  10. ncbi request reprint Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults
    P Picci
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Curr Oncol Rep 2:502-7. 2000

Detail Information

Publications158 found, 100 shown here

  1. doi request reprint Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines
    Claudia M Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Genes Chromosomes Cancer 48:289-309. 2009
    ..These results indicate that resistance to DX and MTX in human OS cell lines is a multigenic process involving gene copy number and expression changes...
  2. pmc Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed
    Stefano Ferrari
    Anti Tumour Drugs Section Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    J Transl Med 11:268. 2013
    ..In this study, we investigated the effects of PPI in chemosensitizing osteosarcoma...
  3. pmc An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas
    Clara Guerzoni
    PROMETEO Laboratory, Section of Biomolecular Therapies, RIT Department, Istituto Ortopedico Rizzoli, Bologna 40136, Italy
    BMC Cancer 14:137. 2014
    ..In this paper we evaluated the in vitro and in vivo efficacy of a new maltol derived molecule (maltonis), belonging to the family of molecules named hydroxypyrones...
  4. pmc Solitary fibrous tumors of the soft tissues: imaging features with histopathologic correlations
    Zafaria G Papathanassiou
    The Rizzoli Institute, via del Barbiano 1 10, 40136, Bologna, Italy
    Clin Sarcoma Res 3:1. 2013
    ..To describe the imaging features of soft tissue solitary fibrous tumors, with histopathological correlations and clinical outcome...
  5. pmc Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Clin Sarcoma Res 2:4. 2012
    ..A more aggressive appearing fibrosarcoma may arise in DFSP, changing its biological behavior. CD34 and apolipoprotein-D are highly expressed in DFSP, but their prognostic significance is uncertain...
  6. pmc Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
    Ymera Pignochino
    Division of Medical Oncology, University of Torino Medical School, A, O, Ordine Mauriziano, Institute for Cancer Research and Treatment Candiolo, and Regina Margherita Children s Hospital, Torino, Italy
    Mol Cancer 8:118. 2009
    ..Despite improved prognosis, metastatic or relapsed OS remains largely incurable and no significant improvement has been observed in the last 20 years. Therefore, the search for alternative agents in OS is mandatory...
  7. pmc Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
    Melissa Paoloni
    Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 10:625. 2009
    ....
  8. pmc Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone
    Maurice Balke
    Department of Orthopaedic Surgery, University of Munster, Munster, Germany
    BMC Cancer 10:462. 2010
    ..GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts...
  9. pmc Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors
    Suvi Savola
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki, Helsinki, Finland
    BMC Cancer 9:17. 2009
    ..Our genome-wide high-resolution analysis aspired to pinpoint genomic regions of highest interest and possible target genes in these areas...
  10. ncbi request reprint Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults
    P Picci
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Curr Oncol Rep 2:502-7. 2000
    ..Both studies confirm the advantage of adjuvant chemotherapy in disease-free and overall surivall in very select groups of high-grade sarcomas of the extremities...
  11. doi request reprint Late sarcoma development after curettage and bone grafting of benign bone tumors
    Piero Picci
    Bone Tumor Center, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Radiol 77:19-25. 2011
    ..Rarely sarcomas develop in previous benign lesions, after a long term disease free interval. We report the experience on these rare cases observed at a single Institution...
  12. pmc Osteosarcoma (osteogenic sarcoma)
    Piero Picci
    Rizzoli Orthopaedic Institute, Scientific Institution for Research Hospitalization and Health Care, Bologna, Italy
    Orphanet J Rare Dis 2:6. 2007
    ..Surgery is conservative (limb salvage) in more than 90% of patients. Prognosis is more severe (cure rate about 30%) for tumours located in the axial skeleton and in patients with metastasis at onset...
  13. doi request reprint Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
    P Picci
    Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 21:1366-73. 2010
    ..The purpose of this study was to analyze improvements in overall survival over 21 years (1982-2002), with a 5-year minimum follow-up, in the largest series from a single center ever reported...
  14. ncbi request reprint Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli
    G Bacci
    Departments of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4-11. 2000
    ..The identification of prognostic factors in patients with nonmetastatic Ewing's sarcoma could allow the use of risk-adapted therapeutic strategies of treatment...
  15. ncbi request reprint Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
    G Bacci
    Service of Chemotherapy, Laboratory of Pathology, Fifth Service of Orthopedic Surgery, and Laboratory of Oncologic Research, Department of Musculoskeletal Oncology, I F Goidanich of the Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4016-27. 2000
    ..To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years...
  16. ncbi request reprint A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Surg Oncol 27:98-104. 2001
    ..Our experience of pre-operative intraarterial (i.a.) vs intravenous (i.v.) infusion of cisplatinum (CDP) in a multiagent neo-adjuvant chemotherapy for osteosarcoma of the extremity is reported...
  17. ncbi request reprint Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Acta Oncol 37:671-6. 1998
    ..The analysis of event-free survival in 158 patients with a 4-year minimum follow-up confirmed that histological response to preoperative chemotherapy is a reliable predictor of outcome in Ewing's sarcoma...
  18. ncbi request reprint Osteosarcoma in blood relatives
    A Longhi
    Service of Chemotherapy, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Oncol Rep 8:131-6. 2001
    ..These findings confirm that specific genetic alterations occur in osteosarcoma pathogenesis...
  19. ncbi request reprint CD99 engagement: an effective therapeutic strategy for Ewing tumors
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 60:5134-42. 2000
    ..These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement...
  20. ncbi request reprint Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Acta Oncol 37:41-8. 1998
    ..Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients...
  21. ncbi request reprint No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies
    G Bacci
    Department of Internal Medicine and Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 5:247-57. 1993
    ..These findings stress the need to find more effective chemotherapeutic regimens for the associated treatment of this tumor...
  22. ncbi request reprint Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 7:230-9. 1995
    ..Prolongation of time relapsed after more effective regimens of adjuvant and neoadjuvant chemotherapy should be considered when evaluating the preliminary results of new chemotherapy protocols...
  23. ncbi request reprint The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively
    G Bacci
    Servizio Medicina Interna, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 2:127-35. 1990
    ....
  24. ncbi request reprint Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities
    G Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 4:189-95. 1992
    ..A longer follow-up is necessary to establish if this improved good response rate achieved with IA CDDP will lead to an improved cure rate.(ABSTRACT TRUNCATED AT 250 WORDS)..
  25. doi request reprint Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
    I Scionti
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 19:1500-8. 2008
    ..Aims of this study were the validation of C-MYC involvement in methotrexate (MTX) resistance and the assessment of clinical impact of C-MYC and dihydrofolate reductase (DHFR) in osteosarcoma (OS)...
  26. ncbi request reprint Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies
    G Bacci
    Department of Chemotherapy, Istituto Rizzoli, Bologna, Italy
    J Chemother 5:237-46. 1993
    ....
  27. ncbi request reprint Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma
    P Ragazzini
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 19:401-11. 2004
    ..These two seem to have a more similar behavior than anaplastic and classic embryonal that are classified in the same subtype...
  28. ncbi request reprint Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities
    P Picci
    Department of Pathology, Rizzoli Orthopedic Institute, Bologna, Italy
    J Clin Oncol 15:1553-9. 1997
    ..This study was performed to assess the prognostic value of the proposed histopathologic method to evaluate the response of the primary tumor to preoperative chemotherapy in Ewing's sarcoma...
  29. ncbi request reprint Alteration of pRb/p16/cdk4 regulation in human osteosarcoma
    M S Benassi
    Department of Musculoskeletal Oncology, Laboratory of Oncologic Research, Rizzoli Orthopedic Institute, Bologna, Italy
    Int J Cancer 84:489-93. 1999
    ..These data confirm the role of the pRb/p16/cdk4 pathway in OS development...
  30. ncbi request reprint Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma
    M S Benassi
    Department of Musculoskeletal Oncology, Laboratory of Oncologic Research, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 92:3062-7. 2001
    ..It encodes two transcripts, p16 and p14 alternate reading frame (ARF), involved in retinoblastoma protein (pRb)- and p53- cell growth control pathways, respectively...
  31. ncbi request reprint Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index
    M R Sollazzo
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Tumori 85:167-73. 1999
    ..CONCLUSION: These results suggest a possible role of the c-myc oncogene and Ki67 antigen in the malignant progression of Ewing's sarcoma...
  32. ncbi request reprint Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas
    M S Benassi
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 22:1017-24. 2007
    ....
  33. ncbi request reprint Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study
    G Bacci
    Sezione di Chemioterapia dei Tumori Ossei, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 8:70-81. 1996
    ..In the IA group, however, there was only one local recurrence vs 5 in the IV group. The IA infusion of CDP is more active on the primary tumor than the IV infusion...
  34. ncbi request reprint Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells
    S Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Clin Cancer Res 7:1790-7. 2001
    ..In conclusion, we showed that, in ES, the blockage of IGF-IR by a neutralizing MAb or by suramin may greatly potentiate the antitumor activity of conventional chemotherapeutic drugs...
  35. ncbi request reprint Primary lymphoma of bone: long term results in patients treated with vincristine--adriamycin--cyclophosphamide and local radiation
    G Bacci
    Bone Tumor Center Istituto Rizzoli, Bologna, Italy
    J Chemother 3:189-93. 1991
    ..No local recurrences nor second tumor in the irradiated field were observed. We conclude that the addition of chemotherapy to radiotherapy results in an excellent cure rate for patients with PLB...
  36. ncbi request reprint Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities
    G Bacci
    Chemotherapy Department, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 6:204-10. 1994
    ....
  37. doi request reprint Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
    S Ferrari
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 22:1221-7. 2011
    ..High-dose chemotherapy (HDT) was added to conventional chemotherapy in Ewing sarcoma family tumor (EFT) patients, poor responders (PRs) to induction chemotherapy in order to improve their survival...
  38. ncbi request reprint Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 18:2037-40. 2007
    ..Post 5-year follow-up for these patients was 9.7 years (5.5-29 years)...
  39. ncbi request reprint Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes
    L Pazzaglia
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 24:61-7. 2009
    ....
  40. ncbi request reprint Metalloproteinase expression and prognosis in soft tissue sarcomas
    M S Benassi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Ann Oncol 12:75-80. 2001
    ..This study assessed the prognostic role of MMP2, MMP9 metalloproteinases, and of the metalloproteinase inhibitor TIMP2, related to disease-free survival (DFS), in soft tissue sarcoma (STS) patients...
  41. ncbi request reprint Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Dipartimento Goidanich, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 87:328-35. 2000
    ..Detection of EWS/FLI-1 fusion transcripts in giant-cell tumor of bone provides a model for the study of the transforming mechanisms of the EWS/FLI-1 fusion gene in mesenchymal tumors...
  42. ncbi request reprint Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions)
    G Bacci
    Sezione Chemioterapia Tumori Ossei, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 78:200-6. 1992
    ..The data suggest that a very effective neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities gives disappointing results in osteosarcoma of the extremities which is metastatic at presentation...
  43. ncbi request reprint Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity
    L Pazzaglia
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 21:187-95. 2006
    ..These findings confirm the genetic complexity of monophasic synovial sarcoma and underline the need to integrate different analyses for a better knowledge of this tumour, essential to investigate new diagnostic and prognostic markers...
  44. ncbi request reprint Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute
    S Ferrari
    Chemotherapy, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 12:1145-50. 2001
    ..To identify predictive factors of disease-free survival (DFS) in patients with non-metastatic osteosarcoma of the extremity, treated with primary chemotherapy and delayed surgery...
  45. ncbi request reprint Metastatic patterns in osteosarcoma
    G Bacci
    Bone Tumor Center, Istituto Ortopedico Rizzoli, Bologna, Italia
    Tumori 74:421-7. 1988
    ..This alteration in metastatic pattern due to adjuvant chemotherapy is important because it allows surgical resection of pulmonary metastases in a larger number of patients (51% vs 29%)...
  46. ncbi request reprint Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours
    G Bacci
    Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 89:1229-33. 2007
    ..We concluded that in ESFT the site, the serum level of lactic dehydrogenase, fever, and the interval between the onset of symptoms and diagnosis are indicators of tumours having a particularly aggressive metastatic behaviour...
  47. doi request reprint Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma
    S Ferrari
    Department Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Pediatr Blood Cancer 52:581-4. 2009
    ..To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT)...
  48. doi request reprint CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity
    C Zucchini
    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
    Oncogene 33:1912-21. 2014
    ....
  49. ncbi request reprint Presence and expression of the simian virus-40 genome in human giant cell tumors of bone
    G Gamberi
    Laboratory of Oncologic Research, Rizzoli Institute, Bologna, Italy
    Genes Chromosomes Cancer 28:23-30. 2000
    ..001). These results show that SV40 DNA sequences and SV40 Tag are present in GCTs and might induce FOS activity. These data suggest that SV40 might play a role in the development and progression of some GCTs...
  50. ncbi request reprint Simultaneous paired analysis of numerical chromosomal aberrations and DNA content in osteosarcoma
    M Serra
    Laboratorio di Ricerca OncologicaIstituti Ortopedici Rizzoli, Bologna, Italy
    Mod Pathol 14:710-6. 2001
    ....
  51. ncbi request reprint Primary chemotherapy and delayed surgery for malignant fibrous histiocytoma of bone in the extremity
    G Bacci
    Centro di Chemioterapia Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 76:537-42. 1990
    ....
  52. ncbi request reprint Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation
    P Picci
    Department of Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 12:1601-4. 2001
    ..CONCLUSION: CT positive predictive value is limited, but as surgery is the only way to cure metastatic patients, CT will still be used as the reference technique until a more specific approach can be found...
  53. ncbi request reprint Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone
    G Gamberi
    Laboratory of Oncologic Research, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 15:498-503. 2004
    ..Few prognostic markers have been reported to predict the clinical outcome of GCT patients, so is very important to find the factor that can be implicated in its potential aggressiveness...
  54. ncbi request reprint Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients
    G Bacci
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Joint Surg Br 88:1071-5. 2006
    ....
  55. ncbi request reprint Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma
    P Ragazzini
    Laboratory of Oncologic Research, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer Detect Prev 23:129-36. 1999
    ..SAS was found amplified in 15% of the samples. These findings indicate that these genes may be involved in tumorigenesis and progression of low-grade osteosarcoma...
  56. ncbi request reprint Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 patients
    E Palmerini
    Istituto Ortopedico Rizzoli, Bologna, Italy University of Bologna Istituto Rizzoli, Bologna, Italy City Hospital, Ravenna, Italy Pediatric Oncohematology, Regina Margherita Children s Hospital, Turin, Italy
    J Clin Oncol 29:10039. 2011
    ..10039 Background: Treatment of pelvic and sacrum osteosarcoma (OS) poses challenges for local control and outcome. Data are scarce since these patients (pts) are often not eligible for chemotherapy protocols...
  57. ncbi request reprint Radiological study of 12 high-grade surface osteosarcomas
    D Vanel
    Laboratorio di Ricerca Oncologica, Institute Rizzoli, Bologna, Italy
    Skeletal Radiol 30:667-71. 2001
    ..The purpose of our study was to report the imaging characteristics of 12 high-grade surface osteosarcomas, diagnosed, staged, treated and followed up in a single institution...
  58. ncbi request reprint Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999
    G Bacci
    Section of Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    Eur J Surg Oncol 32:974-9. 2006
    ..Evaluation of pattern of recurrences of 290 patients with an Ewing's sarcoma family tumor (ESFT), who relapsed after adjuvant or neoadjuvant chemotherapy...
  59. ncbi request reprint The Istituto Rizzoli experience with small cell osteosarcoma
    F Bertoni
    Istituto Orthopedico Rizzoli, Bologna, Italy
    Cancer 64:2591-9. 1989
    ..The lesion may mimic Ewing's tumor and other lesions in which round cells are seen. We report the clinical, radiologic, and pathologic features of this tumor, as well as the clinical outcome and response to therapy...
  60. ncbi request reprint Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas
    M S Benassi
    Oncological Research Laboratory, Istituti Ortopedici Rizzoli, Bologna, Italy
    Histol Histopathol 18:1035-40. 2003
    ..0001). In conclusion, low levels of negative regulators of proteolysis may be related to tumor biological aggressiveness and used to select patients with poor prognosis to improve cure...
  61. pmc CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis
    Anna Rocchi
    Laboratory of Experimental Oncology, CRS Development of Biomolecular Therapies, SSN Emilia Romagna Istituti Ortopedici Rizzoli IRCCS, Bologna, Italy
    J Clin Invest 120:668-80. 2010
    ..Together, these data indicate a new role for CD99 in preventing neural differentiation of EWS cells and suggest that blockade of CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS...
  62. doi request reprint Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma
    Michela Pasello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 68:6661-8. 2008
    ....
  63. ncbi request reprint High-dose chemotherapy with autologous stem cell transplantation for relapsed Ewing's sarcoma
    E Palmerini
    Istituto Ortopedico Rizzoli, Bologna, Italy Ospedale Regina Margherita, Torino, Italy Istituto Nazionale Tumori, Milano, Italy Ospedale S Orsola Malpighi, Bologna, Italy Ospedale A Meyer, Firenze, Italy Ospedale S Maria Delle Croci, Ravenna, Italy
    J Clin Oncol 27:10545. 2009
    ..In order to improve PRS, we employed HDCT with ASCT in EWS patients at 1st relapse...
  64. ncbi request reprint Survival in high-grade osteosarcoma: Improvement in a 21-year period at a single institution
    P Picci
    Istituto Ortopedici Rizzoli, Bologna, Italy Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 27:10515. 2009
    ..Data are also analyzed in subgroups to define patients who benefited most...
  65. doi request reprint Parosteal osteosarcoma dedifferentiating into telangiectatic osteosarcoma: importance of lytic changes and fluid cavities at imaging
    M Azura
    Musculoskeletal Oncological Surgery Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna 40136, Italy
    Skeletal Radiol 38:685-90. 2009
    ..Only one case of differentiation into a telangiectatic osteosarcoma has been reported. As it has practical consequences, with a need for aggressive chemotherapy, we looked for this rather typical imaging pattern...
  66. ncbi request reprint Bone hemangioendothelioma: an immunohistochemical study related to histological malignancy and proliferative activity (NORs)
    M S Benassi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Tumori 81:179-84. 1995
    ..CONCLUSIONS: The mean nucleolar organizer region (NOR) area, as a measure of cell proliferation, was significantly higher in grade 4 malignancies than in lower grades, revealing novel prognostic parameters...
  67. ncbi request reprint 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients
    Michela Pasello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Eur J Cancer 41:2184-95. 2005
    ....
  68. ncbi request reprint Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling
    Lara Cantiani
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Italy
    Cancer Res 67:7675-85. 2007
    ..These data strengthen the rationale to target c-Src family kinases and/or Met receptor to improve the extremely poor prognosis of metastatic osteosarcoma...
  69. ncbi request reprint Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 108:358-66. 2004
    ..Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES...
  70. doi request reprint Sclerosing epithelioid fibrosarcoma of the thigh: report of two cases with synchronous bone metastases
    A Righi
    Department of Pathology, Rizzoli Institute, Via Di Barbiano 1 10, 40136, Bologna, Italy
    Virchows Arch 467:339-44. 2015
    ....
  71. pmc Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
    E Tavanti
    Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Via Di Barbiano 1 10, I 40136 Bologna, Italy
    Br J Cancer 109:2607-18. 2013
    ..Aurora kinases are key regulators of cell cycle and represent new promising therapeutic targets in several human tumours...
  72. ncbi request reprint Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells
    R Strammiello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Horm Metab Res 35:675-84. 2003
    ..Taken together, these findings add a new activity to the IGF-I repertoire in ES and highlight how disruption of IGF-IR functions may constitute an effective tool for the control of neovascularization in this tumor...
  73. ncbi request reprint CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Oncogene 26:6604-18. 2007
    ..In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules...
  74. ncbi request reprint High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study
    G Bacci
    Sezione di Chemioterapia, Instituto Ortopedico Rizzoli, Bologna, Italy
    J Chemother 14:198-206. 2002
    ..On the basis of this study, in March 1997 the Italian and Scandinavian Sarcoma Groups started a new protocol for osteosarcoma of the extremities...
  75. ncbi request reprint Prognostic value of serum alkaline phosphatase in osteosarcoma
    G Bacci
    Bone Tumor Center, Bologna, Italia
    Tumori 73:331-6. 1987
    ....
  76. doi request reprint NVP-BEZ235 as a new therapeutic option for sarcomas
    Maria C Manara
    Laboratorio di Ricerca Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy
    Clin Cancer Res 16:530-40. 2010
    ..To evaluate the in vitro and in vivo effects of NVP-BEZ235, a dual pan-phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor in the three most common musculoskeletal tumors (osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma)...
  77. ncbi request reprint Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells
    Giuliana Gobbi
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Int J Oncol 20:143-7. 2002
    ..No mutations were detected in the BMPR-II cDNA. Our results suggest the presence of a mechanism involving the simultaneous activation of the BMPs and their receptors in osteosarcoma cell lines...
  78. ncbi request reprint Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 119:1039-46. 2006
    ..IGFBP-3 acts mainly through IGF-dependent mechanisms and the protein may therefore represent an alternative strategy to inhibit IGF-IR functions. The data indicate IGFBP-3 as a molecule of therapeutic potential in EWS...
  79. ncbi request reprint Giant notochordal rests misdiagnosed and treated as chordomas. A retrospective clinical, radiological and histologic study of four cases
    P Picci
    Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 26:21503. 2008
    ..Out of 350 chordomas found in the files of our institution, four were actually notochordal rests. A review of the clinical radiological and histologic data was made...
  80. doi request reprint Imaging of bone tumors for the musculoskeletal oncologic surgeon
    C Errani
    Department of Orthopaedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy Electronic address
    Eur J Radiol 82:2083-91. 2013
    ....
  81. doi request reprint Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone
    M Alberghini
    Istituto Ortopedico Rizzoli, Bologna, Italy
    Virchows Arch 456:97-103. 2010
    ..Our findings suggest that most lung nodules associated with primary conventional GCTBs are implants derived from tumour emboli formed in areas of haemorrhage and thrombus formation within the primary tumour...
  82. ncbi request reprint Radiological features of 24 periosteal chondrosarcomas
    D Vanel
    Laboratorio di Ricerca Oncologica, Istituto Rizzoli, Bologna, Italy
    Skeletal Radiol 30:208-12. 2001
    ..CONCLUSIONS: Recognizing periosteal chondrosarcoma is of paramount importance because the prognosis is excellent after adequate local surgery alone. The patterns of other surface tumors of bone are usually different...
  83. ncbi request reprint Targeted therapies in bone sarcomas
    K Scotlandi
    Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy
    Curr Cancer Drug Targets 9:843-53. 2009
    ..The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets...
  84. doi request reprint Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)
    Diana Zambelli
    Laboratory of Oncologic Research, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 126:41-52. 2010
    ..Thus, we propose LGALS3BP as a novel reliable indicator of prognosis, and we offer genetic signatures to the scientific communities for cross-validation and meta-analysis, which are indispensable tools for a rare tumor such as EWS...
  85. doi request reprint Prognostic value of CCN3 in osteosarcoma
    Bernard Perbal
    Laboratorio di Ricerca Oncologica and Laboratorio di Rigenerazione Tissutale Ossea, Istituti Ortopedici Rizzoli, Bologna, Italy
    Clin Cancer Res 14:701-9. 2008
    ..We assessed the prognostic value of CCN1, CCN2, and CCN3 genes, involved in fundamental biological processes...
  86. pmc The expression of ccn3(nov) gene in musculoskeletal tumors
    Maria Cristina Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Am J Pathol 160:849-59. 2002
    ..Further studies will help to clarify the biological role of this protein in musculoskeletal neoplasms...
  87. ncbi request reprint Murine model for skeletal metastases of Ewing's sarcoma
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Universita degli Studi di Bologna, Italy
    J Orthop Res 18:959-66. 2000
    ..This experimental model of bone metastasis of Ewing's sarcoma may be the basis for future studies aimed at understanding the pathophysiology and treatment of Ewing's sarcoma...
  88. ncbi request reprint Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response
    S Ferrari
    Chemioterapia, I Clinica Ortopedica dell Università di Bologna, Italy
    Tumori 85:458-64. 1999
    ..Additional aims were to assess the role of the route of infusion (intraarterial or intravenous) of cisplatin on histologic response of the primary tumor and the use of ifosfamide as salvage chemotherapy in poor responders...
  89. ncbi request reprint P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy
    N Baldini
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, University of Bologna, Italy
    J Orthop Res 17:629-32. 1999
    ..Standard programs are sufficient for P-glycoprotein-negative osteosarcomas, whereas P-glycoprotein-positive tumors may benefit from the use of more intensive therapeutic approaches...
  90. pmc From a 16th century monastery to a 21st century orthopaedic hospital
    P Tomba
    Library, Institute Orthopedic Rizzoli, Bologna, Italy
    BMJ 333:1328-30. 2006
  91. pmc The incidental skeletal lesion: ignore or explore?
    D Vanel
    The Rizzoli Institute, Bologna 40106, Italy
    Cancer Imaging 9:S38-43. 2009
    ..There are very typical cases, and there are also more difficult ones, and they can be especially difficult to manage if the patient has a known cancer...
  92. ncbi request reprint C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica and Servicio di Anatomia Patologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    J Clin Oncol 21:1952-60. 2003
    ..Autocrine/paracrine stimulation of c-kit has been recently observed in Ewing's sarcoma (ES) cell lines. In this study, we tested the prognostic and therapeutic role of the receptor in this tumor...
  93. doi request reprint Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience
    Gaetano Bacci
    Chemotherapy Unit, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:908-12. 2008
    ..20%). The authors conclude that there does not seem to be any indication to treat preadolescent primary high-grade nonmetastatic osteosarcoma patients by alternative and/or more aggressive therapies...
  94. doi request reprint Targeting insulin-like growth factor 1 receptor in sarcomas
    Katia Scotlandi
    Laboratory of Oncologic Research, Istituti Ortopedici Rizzoli, Bologna, Italy
    Curr Opin Oncol 20:419-27. 2008
    ....
  95. doi request reprint NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients
    Maria Serena Benassi
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Orthop Res 27:135-40. 2009
    ....
  96. ncbi request reprint Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival
    Stefano Ferrari
    Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Clin Oncol 21:710-5. 2003
    ..To identify factors that influence postrelapse survival (PRS) in patients with nonmetastatic osteosarcoma of the extremity...
  97. ncbi request reprint Identification of markers of possible prognostic value in 57 giant cell tumors of bone
    Gabriella Gamberi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, I 40136 Bologna, Italy
    Oncol Rep 10:351-6. 2003
    ..Therefore, the evaluation of the expression levels of these proteins at the time of diagnosis may be taken into consideration for a classification of GCT into categories characterized by a different risk to relapse...
  98. ncbi request reprint Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Sezione di Chemioterapia, Servizio di Anatomia Patologica, Va Divisione, and Unita di Chirurgia Generale, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Clin Oncol 21:536-42. 2003
    ..To evaluate the prognostic value of P-glycoprotein and clinicopathologic parameters in a large series of high-grade osteosarcoma (OS) patients treated at the Rizzoli Institute...
  99. ncbi request reprint Troglitazione affects survival of human osteosarcoma cells
    Enrico Lucarelli
    Laboratory of Oncology Research, Rizzoli Orthopedic Institute, Bologna, Italy
    Int J Cancer 98:344-51. 2002
    ..Our work describes a new function for TRO and indicates that the Akt survival pathway may be a mediator of TRO-induced increase of survival...
  100. ncbi request reprint Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Gene Ther 9:296-307. 2002
    ..These results indicate that inhibiting IGF-IR by antisense strategies may be relevant to the clinical treatment of ES patients by reducing the malignant potential of these cells and enhancing the effectiveness of chemotherapy...
  101. doi request reprint Prognostic relevance of CCN3 in Ewing sarcoma
    Bernard Perbal
    Rizzoli Orthopaedic Institute, Bologna, Italy
    Hum Pathol 40:1479-86. 2009
    ..We hypothesize that the increased level of variant CCN3 in the tumor cells reduces their tumorigenic potential and results in better outcome...